Report cover image

Global Peptic Ulcer Medication Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 193 Pages
SKU # APRC20282611

Description

Summary

According to APO Research, The global Peptic Ulcer Medication market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Peptic Ulcer Medication is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Peptic Ulcer Medication is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Peptic Ulcer Medication is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Peptic Ulcer Medication is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Peptic Ulcer Medication include AstraZeneca, Chongqing Lummy Pharmaceutical, CTTQ, Jumpcan Pharmaceutical, Livzon Pharmaceutical, Luoxin Pharmaceuticals, Youcare Pharmaceutical, Jiangsu Aosaikang Pharmaceutical and Teva Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Peptic Ulcer Medication, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Peptic Ulcer Medication, also provides the revenue of main regions and countries. Of the upcoming market potential for Peptic Ulcer Medication, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptic Ulcer Medication revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Peptic Ulcer Medication market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Peptic Ulcer Medication revenue, projected growth trends, production technology, application and end-user industry.

Peptic Ulcer Medication Segment by Company

AstraZeneca
Chongqing Lummy Pharmaceutical
CTTQ
Jumpcan Pharmaceutical
Livzon Pharmaceutical
Luoxin Pharmaceuticals
Youcare Pharmaceutical
Jiangsu Aosaikang Pharmaceutical
Teva Pharmaceuticals
Eisai
Takeda
Zhejiang Conba Pharmaceutical
Peptic Ulcer Medication Segment by Type

Proton Pump Inhibitors
Antacids
H2-Receptor Antagonists
Others
Peptic Ulcer Medication Segment by Application

Hospital and Clinic
Pharmacy
Peptic Ulcer Medication Segment by Region

North America
United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptic Ulcer Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptic Ulcer Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptic Ulcer Medication.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Peptic Ulcer Medication in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Peptic Ulcer Medication company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptic Ulcer Medication revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Peptic Ulcer Medication Market by Type
1.2.1 Global Peptic Ulcer Medication Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Proton Pump Inhibitors
1.2.3 Antacids
1.2.4 H2-Receptor Antagonists
1.2.5 Others
1.3 Peptic Ulcer Medication Market by Application
1.3.1 Global Peptic Ulcer Medication Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Peptic Ulcer Medication Market Dynamics
2.1 Peptic Ulcer Medication Industry Trends
2.2 Peptic Ulcer Medication Industry Drivers
2.3 Peptic Ulcer Medication Industry Opportunities and Challenges
2.4 Peptic Ulcer Medication Industry Restraints
3 Global Growth Perspective
3.1 Global Peptic Ulcer Medication Market Perspective (2020-2031)
3.2 Global Peptic Ulcer Medication Growth Trends by Region
3.2.1 Global Peptic Ulcer Medication Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Peptic Ulcer Medication Market Size by Region (2020-2025)
3.2.3 Global Peptic Ulcer Medication Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Peptic Ulcer Medication Revenue by Players
4.1.1 Global Peptic Ulcer Medication Revenue by Players (2020-2025)
4.1.2 Global Peptic Ulcer Medication Revenue Market Share by Players (2020-2025)
4.1.3 Global Peptic Ulcer Medication Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Peptic Ulcer Medication Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Peptic Ulcer Medication Key Players Headquarters & Area Served
4.4 Global Peptic Ulcer Medication Players, Product Type & Application
4.5 Global Peptic Ulcer Medication Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Peptic Ulcer Medication Market CR5 and HHI
4.6.3 2024 Peptic Ulcer Medication Tier 1, Tier 2, and Tier 3
5 Peptic Ulcer Medication Market Size by Type
5.1 Global Peptic Ulcer Medication Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Peptic Ulcer Medication Revenue by Type (2020-2031)
5.3 Global Peptic Ulcer Medication Revenue Market Share by Type (2020-2031)
6 Peptic Ulcer Medication Market Size by Application
6.1 Global Peptic Ulcer Medication Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Peptic Ulcer Medication Revenue by Application (2020-2031)
6.3 Global Peptic Ulcer Medication Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Comapny Information
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Peptic Ulcer Medication Revenue and Gross Margin (2020-2025)
7.1.4 AstraZeneca Peptic Ulcer Medication Product Portfolio
7.1.5 AstraZeneca Recent Developments
7.2 Chongqing Lummy Pharmaceutical
7.2.1 Chongqing Lummy Pharmaceutical Comapny Information
7.2.2 Chongqing Lummy Pharmaceutical Business Overview
7.2.3 Chongqing Lummy Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (2020-2025)
7.2.4 Chongqing Lummy Pharmaceutical Peptic Ulcer Medication Product Portfolio
7.2.5 Chongqing Lummy Pharmaceutical Recent Developments
7.3 CTTQ
7.3.1 CTTQ Comapny Information
7.3.2 CTTQ Business Overview
7.3.3 CTTQ Peptic Ulcer Medication Revenue and Gross Margin (2020-2025)
7.3.4 CTTQ Peptic Ulcer Medication Product Portfolio
7.3.5 CTTQ Recent Developments
7.4 Jumpcan Pharmaceutical
7.4.1 Jumpcan Pharmaceutical Comapny Information
7.4.2 Jumpcan Pharmaceutical Business Overview
7.4.3 Jumpcan Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (2020-2025)
7.4.4 Jumpcan Pharmaceutical Peptic Ulcer Medication Product Portfolio
7.4.5 Jumpcan Pharmaceutical Recent Developments
7.5 Livzon Pharmaceutical
7.5.1 Livzon Pharmaceutical Comapny Information
7.5.2 Livzon Pharmaceutical Business Overview
7.5.3 Livzon Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (2020-2025)
7.5.4 Livzon Pharmaceutical Peptic Ulcer Medication Product Portfolio
7.5.5 Livzon Pharmaceutical Recent Developments
7.6 Luoxin Pharmaceuticals
7.6.1 Luoxin Pharmaceuticals Comapny Information
7.6.2 Luoxin Pharmaceuticals Business Overview
7.6.3 Luoxin Pharmaceuticals Peptic Ulcer Medication Revenue and Gross Margin (2020-2025)
7.6.4 Luoxin Pharmaceuticals Peptic Ulcer Medication Product Portfolio
7.6.5 Luoxin Pharmaceuticals Recent Developments
7.7 Youcare Pharmaceutical
7.7.1 Youcare Pharmaceutical Comapny Information
7.7.2 Youcare Pharmaceutical Business Overview
7.7.3 Youcare Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (2020-2025)
7.7.4 Youcare Pharmaceutical Peptic Ulcer Medication Product Portfolio
7.7.5 Youcare Pharmaceutical Recent Developments
7.8 Jiangsu Aosaikang Pharmaceutical
7.8.1 Jiangsu Aosaikang Pharmaceutical Comapny Information
7.8.2 Jiangsu Aosaikang Pharmaceutical Business Overview
7.8.3 Jiangsu Aosaikang Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (2020-2025)
7.8.4 Jiangsu Aosaikang Pharmaceutical Peptic Ulcer Medication Product Portfolio
7.8.5 Jiangsu Aosaikang Pharmaceutical Recent Developments
7.9 Teva Pharmaceuticals
7.9.1 Teva Pharmaceuticals Comapny Information
7.9.2 Teva Pharmaceuticals Business Overview
7.9.3 Teva Pharmaceuticals Peptic Ulcer Medication Revenue and Gross Margin (2020-2025)
7.9.4 Teva Pharmaceuticals Peptic Ulcer Medication Product Portfolio
7.9.5 Teva Pharmaceuticals Recent Developments
7.10 Eisai
7.10.1 Eisai Comapny Information
7.10.2 Eisai Business Overview
7.10.3 Eisai Peptic Ulcer Medication Revenue and Gross Margin (2020-2025)
7.10.4 Eisai Peptic Ulcer Medication Product Portfolio
7.10.5 Eisai Recent Developments
7.11 Takeda
7.11.1 Takeda Comapny Information
7.11.2 Takeda Business Overview
7.11.3 Takeda Peptic Ulcer Medication Revenue and Gross Margin (2020-2025)
7.11.4 Takeda Peptic Ulcer Medication Product Portfolio
7.11.5 Takeda Recent Developments
7.12 Zhejiang Conba Pharmaceutical
7.12.1 Zhejiang Conba Pharmaceutical Comapny Information
7.12.2 Zhejiang Conba Pharmaceutical Business Overview
7.12.3 Zhejiang Conba Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (2020-2025)
7.12.4 Zhejiang Conba Pharmaceutical Peptic Ulcer Medication Product Portfolio
7.12.5 Zhejiang Conba Pharmaceutical Recent Developments
8 North America
8.1 North America Peptic Ulcer Medication Revenue (2020-2031)
8.2 North America Peptic Ulcer Medication Revenue by Type (2020-2031)
8.2.1 North America Peptic Ulcer Medication Revenue by Type (2020-2025)
8.2.2 North America Peptic Ulcer Medication Revenue by Type (2026-2031)
8.3 North America Peptic Ulcer Medication Revenue Share by Type (2020-2031)
8.4 North America Peptic Ulcer Medication Revenue by Application (2020-2031)
8.4.1 North America Peptic Ulcer Medication Revenue by Application (2020-2025)
8.4.2 North America Peptic Ulcer Medication Revenue by Application (2026-2031)
8.5 North America Peptic Ulcer Medication Revenue Share by Application (2020-2031)
8.6 North America Peptic Ulcer Medication Revenue by Country
8.6.1 North America Peptic Ulcer Medication Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Peptic Ulcer Medication Revenue by Country (2020-2025)
8.6.3 North America Peptic Ulcer Medication Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Peptic Ulcer Medication Revenue (2020-2031)
9.2 Europe Peptic Ulcer Medication Revenue by Type (2020-2031)
9.2.1 Europe Peptic Ulcer Medication Revenue by Type (2020-2025)
9.2.2 Europe Peptic Ulcer Medication Revenue by Type (2026-2031)
9.3 Europe Peptic Ulcer Medication Revenue Share by Type (2020-2031)
9.4 Europe Peptic Ulcer Medication Revenue by Application (2020-2031)
9.4.1 Europe Peptic Ulcer Medication Revenue by Application (2020-2025)
9.4.2 Europe Peptic Ulcer Medication Revenue by Application (2026-2031)
9.5 Europe Peptic Ulcer Medication Revenue Share by Application (2020-2031)
9.6 Europe Peptic Ulcer Medication Revenue by Country
9.6.1 Europe Peptic Ulcer Medication Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Peptic Ulcer Medication Revenue by Country (2020-2025)
9.6.3 Europe Peptic Ulcer Medication Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Peptic Ulcer Medication Revenue (2020-2031)
10.2 China Peptic Ulcer Medication Revenue by Type (2020-2031)
10.2.1 China Peptic Ulcer Medication Revenue by Type (2020-2025)
10.2.2 China Peptic Ulcer Medication Revenue by Type (2026-2031)
10.3 China Peptic Ulcer Medication Revenue Share by Type (2020-2031)
10.4 China Peptic Ulcer Medication Revenue by Application (2020-2031)
10.4.1 China Peptic Ulcer Medication Revenue by Application (2020-2025)
10.4.2 China Peptic Ulcer Medication Revenue by Application (2026-2031)
10.5 China Peptic Ulcer Medication Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Peptic Ulcer Medication Revenue (2020-2031)
11.2 Asia Peptic Ulcer Medication Revenue by Type (2020-2031)
11.2.1 Asia Peptic Ulcer Medication Revenue by Type (2020-2025)
11.2.2 Asia Peptic Ulcer Medication Revenue by Type (2026-2031)
11.3 Asia Peptic Ulcer Medication Revenue Share by Type (2020-2031)
11.4 Asia Peptic Ulcer Medication Revenue by Application (2020-2031)
11.4.1 Asia Peptic Ulcer Medication Revenue by Application (2020-2025)
11.4.2 Asia Peptic Ulcer Medication Revenue by Application (2026-2031)
11.5 Asia Peptic Ulcer Medication Revenue Share by Application (2020-2031)
11.6 Asia Peptic Ulcer Medication Revenue by Country
11.6.1 Asia Peptic Ulcer Medication Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Peptic Ulcer Medication Revenue by Country (2020-2025)
11.6.3 Asia Peptic Ulcer Medication Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Peptic Ulcer Medication Revenue (2020-2031)
12.2 SAMEA Peptic Ulcer Medication Revenue by Type (2020-2031)
12.2.1 SAMEA Peptic Ulcer Medication Revenue by Type (2020-2025)
12.2.2 SAMEA Peptic Ulcer Medication Revenue by Type (2026-2031)
12.3 SAMEA Peptic Ulcer Medication Revenue Share by Type (2020-2031)
12.4 SAMEA Peptic Ulcer Medication Revenue by Application (2020-2031)
12.4.1 SAMEA Peptic Ulcer Medication Revenue by Application (2020-2025)
12.4.2 SAMEA Peptic Ulcer Medication Revenue by Application (2026-2031)
12.5 SAMEA Peptic Ulcer Medication Revenue Share by Application (2020-2031)
12.6 SAMEA Peptic Ulcer Medication Revenue by Country
12.6.1 SAMEA Peptic Ulcer Medication Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Peptic Ulcer Medication Revenue by Country (2020-2025)
12.6.3 SAMEA Peptic Ulcer Medication Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.